Alessandro Bonzano

Alessandro Bonzano

Auto-generated profile, based on publicly available information

Alessandro Bonzano

IRCCS Candiolo

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
SGSimona Gallo
Simona Gallo
AVAnnapia Vitacolonna
Annapia Vitacolonna
ABAlessandro Bonzano
Alessandro Bonzano
PCPaolo m Comoglio
Paolo m Comoglio
TCTIZIANA CREPALDI
TIZIANA CREPALDI
Cardiac hypertrophy is an adaptive and compensatory mechanism preserving cardiac output during detrimental stimuli. Nevertheless, long-term stimuli incite chronic hypertrophy and may lead to heart failure. In this review, we analyze the recent literature regarding the role of ERK (extracellular signal-regulated kinase) activity in cardiac hypertrophy. ERK signaling produces beneficial effects during the early phase of chronic pressure overload in response to G protein-coupled receptors (GPCRs) and integrin stimulation. These functions comprise (i) adaptive concentric hypertrophy and (ii) cell death prevention. On the other hand, ERK participates in maladaptive hypertrophy during hypertension and chemotherapy-mediated cardiac side effects. Specific ERK-associated scaffold proteins are implicated in either cardioprotective or detrimental hypertrophic functions. Interestingly, ERK phosphorylated at threonine 188 and activated ERK5 (the big MAPK 1) are associated with pathological forms of hypertrophy. Finally, we examine the connection between ERK activation and hypertrophy in (i) transgenic mice overexpressing constitutively activated RTKs (receptor tyrosine kinases), (ii) animal models with mutated sarcomeric proteins characteristic of inherited hypertrophic cardiomyopathies (HCMs), and (iii) mice reproducing syndromic genetic RASopathies. Overall, the scientific literature suggests that during cardiac hypertrophy, ERK could be a “good” player to be stimulated or a “bad” actor to be mitigated, depending on the pathophysiological context.

1 May 2002 in JACC
Verified
Journal Article
Closed access
EAEmanuele Antonielli
Emanuele Antonielli
APAlfredo Pizzuti
Alfredo Pizzuti
APAttila Pálinkás
Attila Pálinkás
MTMattia Tanga
Mattia Tanga
NGN.OÈmi Gruber
N.OÈmi Gruber
EPEugenio Picano
Eugenio Picano

1 April 2018 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
IDIlaria Depetris
Ilaria Depetris
DMDonatella Marino
Donatella Marino
ABAlessandro Bonzano
Alessandro Bonzano
CCCeleste Cagnazzo
Celeste Cagnazzo
RFRoberto Filippi
Roberto Filippi
FLFrancesco Leone
Francesco Leone

1 December 2001 in European Heart Journal
Verified
Journal Article
Open access
PDF file
APAttila Pálinkás
Attila Pálinkás
EAE. Antonielli
E. Antonielli
EPE. Picano
E. Picano
APA. Pizzuti
A. Pizzuti
AVA. Varga
A. Varga
MCM. Csanády
M. Csanády
Background Echocardiographic parameters for predicting cardioversion outcome in patients with non-valvular atrial fibrillation are not accurately def

23 November 2009 in Acta Neurologica Scandinavica
Verified
Journal Article
Closed access
PDF file
FOF. Orzan
F. Orzan
WLW. Liboni
W. Liboni
ABA. Bonzano
A. Bonzano
FMFilippo Molinari
Filippo Molinari
MRM. Ribezzo
M. Ribezzo
ENE. Negri
E. Negri
Transesophageal echocardiography (TEE) is usually recommended in the evaluation of the patent foramen ovale (PFO). Our goal is to confirm the efficacy of contrast-enhanced transcranial Doppler (ce-TCD) in detecting residual significant right-to-left shunts (RLS) after PFO percutaneous closure. Sixty-eight patients with a previous transient ischemic attack, stroke and a large PFO were investigated for residual RLS after percutaneous closure. Assuming TEE as the gold standard, the sensitivity and negative predictive value of ce-TCD was 100%, whereas the specificity was 75.8% and the positive predictive value was 28%. ce-TCD appears to be the preferable technique to identify subjects with significant residual shunts after percutaneous closure of a PFO. In follow-up, if ce-TCD is negative, no further examination may be necessary; whereas if ce-TCD shows a residual shunt, it is advisable to perform a TEE investigation.

1 April 1995 in Angiology
Verified
Journal Article
Closed access
CCCarlo Caruzzo
Carlo Caruzzo
WLWilliam Liboni
William Liboni
ABAlessandro Bonzano
Alessandro Bonzano
MBMarco Bobbio
Marco Bobbio
SBSergio Bongioanni
Sergio Bongioanni
FCFilippo Civaia
Filippo Civaia
The Prevenzione Aterosclerosi Studio Torino (P.A.S.T.) was a prospective, randomized trial testing the effect on carotid and femoral atherosclerotic lesions of lipid-lowering therapy, as assessed by duplex scanning (DS) technique, in 85 patients (12 women, 73 men), forty-five to fifty-five years old, with ischemic heart disease (IHD), and randomly assigned to a hypolipidemic diet or diet + 250 mg acipimox (a nicotinic acid compound) two to three times/day. Forty-one patients, without inclusion criteria, were compared with the randomized groups as a reference population. All three groups were submitted to DS and to hematic monitoring of lipid levels at the beginning and at the end of the study. During three years of treatment, there was a significant reduction (-6.5%) in total plasma cholesterol in the diet+drug group (P=0.04) and a simultaneous elevation of high-density lipoprotein cholesterol, significant in the treatment groups (respectively, + 15% P=0.02 in the diet and +16% P=0.016 in the diet+drug group). Every group showed a trend toward the increasing number of lesions in all explored areas and toward the progression in size of the already existing ones. Whereas in the initial DS the prevalence of lesions was significantly lower in the nonrandomized group in every site, at the end of the study the total number of lesions did not differ among groups, and there was a significant increase of plaques in carotid area in the nonran domized group in comparison with the treatment groups. (continued on next page) The final number of stable plaques was greater in the treatment groups as compared with the nonrandomized group (P=0.01 diet vs nonrandomized, P=0.03 diet+drug vs nonrandomized). In conclusion, lipid-lowering treatment, with diet and with diet+drug, was useful in slowing the natural progression of atherosclerosis; particularly, it reduced the develop ment of new lesions in the carotid and femoral arteries and increased the stability of the already existing ones. In these patients, diet was equivalent to diet+drug in regard to progression of lesions. The most favorable results in the treatment groups seem to correlate with high-density lipoprotein cholesterol, significantly increased in comparison with the nonrandomized group.